Evidence map›Paper›PMID 32750085›Full record

ArticlePLoS pathogens2020

Galectin-3 enhances neutrophil motility and extravasation into the airways during Aspergillus fumigatus infection.

Brendan D Snarr, Guillaume St-Pierre, Benjamin Ralph, Mélanie Lehoux, Yukiko Sato, Ann Rancourt, Takahiro Takazono, Shane R Baistrocchi, Rachel Corsini, Matthew P Cheng and 11 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Assessing Nanopore Targeted Sequencing for the Diagnosis of Pulmonary Infections: A Comparative Multidisease Approach.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Article
  4. The Historiography of Galactose and Its Recognition by Galectins.Advances in experimental medicine and biology · 2026
    Review
  5. Article
  6. Article
  7. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. The role of galectins in immunity and infection.Nature reviews. Immunology · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Brendan D SnarrDepartment of Microbiology and Immunology, McGill University, Montréal, Canada.
Guillaume St-PierreLaboratory of Glycobiology and Bioimaging, Research Centre for Infectious Diseases, Research Centre of CHU de Québec, Faculty of Medicine, Laval University, Québec City, Canada.
Benjamin RalphDepartment of Microbiology and Immunology, McGill University, Montréal, Canada.ORCID 0000-0002-9464-5410
Mélanie LehouxInfectious Diseases and Immunity in Global Health Program, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montréal, Canada.
Yukiko SatoInfectious Diseases and Immunity in Global Health Program, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montréal, Canada.
Ann RancourtLaboratory of Glycobiology and Bioimaging, Research Centre for Infectious Diseases, Research Centre of CHU de Québec, Faculty of Medicine, Laval University, Québec City, Canada.ORCID 0000-0002-5740-5506
Takahiro TakazonoDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.ORCID 0000-0002-0696-5386
Shane R BaistrocchiInfectious Diseases and Immunity in Global Health Program, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montréal, Canada.ORCID 0000-0003-4553-6151
Rachel CorsiniInfectious Diseases and Immunity in Global Health Program, Centre for Translational Biology, Research Institute of the McGill University Health Centre, Montréal, Canada.
Matthew P ChengDivision of Infectious Diseases and Department of Medical Microbiology, McGill University Health Centre, Montréal, Canada.ORCID 0000-0002-4867-2063
Michele SugrueUniversity of Florida College of Medicine, Gainsville, Florida, United States of America.ORCID 0000-0003-3327-182X
Lindsey R BadenHarvard University & Brigham & Women's Hospital, Boston, Massachusetts, United States of America.
Koichi IzumikawaDepartment of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
John R WingardUniversity of Florida College of Medicine, Gainsville, Florida, United States of America.ORCID 0000-0001-7478-5398
Irah L KingDepartment of Microbiology and Immunology, McGill University, Montréal, Canada.
Maziar DivangahiDepartment of Microbiology and Immunology, McGill University, Montréal, Canada.
Masahiko S SatohLaboratory of DNA Damage Responses and Bioimaging, CHU de Québec, Faculty of Medicine, Laval University, Québec city, Canada.
Bryan G YippCalvin, Phoebe and Joan Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.ORCID 0000-0002-5887-9551
Sachiko SatoLaboratory of Glycobiology and Bioimaging, Research Centre for Infectious Diseases, Research Centre of CHU de Québec, Faculty of Medicine, Laval University, Québec City, Canada.
Donald C SheppardDepartment of Microbiology and Immunology, McGill University, Montréal, Canada.ORCID 0000-0001-8877-880X
McGill University Health Centre · CAUniversité Laval · CANagasaki University · JPUniversity of Florida · USBrigham and Women's Hospital · USUniversity of Calgary · CA

Funding

CIHR 123306CIHR 81361CIHR FDN-159902NCI NIH HHS HHSN261200700023CNIAID NIH HHS N01 AI070023
6 · The paper itself

Abstract

Aspergillus fumigatus is an opportunistic mold that infects patients who are immunocompromised or have chronic lung disease, causing significant morbidity and mortality in these populations. While the factors governing the host response to A. fumigatus remain poorly defined, neutrophil recruitment to the site of infection is critical to clear the fungus. Galectin-3 is a mammalian β-galactose-binding lectin with both antimicrobial and immunomodulatory activities, however the role of galectin-3 in the defense against molds has not been studied. Here we show that galectin-3 expression is markedly up-regulated in mice and humans with pulmonary aspergillosis. Galectin-3 deficient mice displayed increased fungal burden and higher mortality during pulmonary infection. In contrast to previous reports with pathogenic yeast, galectin-3 exhibited no antifungal activity against A. fumigatus in vitro. Galectin-3 deficient mice exhibited fewer neutrophils in their airways during infection, despite normal numbers of total lung neutrophils. Intravital imaging studies confirmed that galectin-3 was required for normal neutrophil migration to the airspaces during fungal infection. Adoptive transfer experiments demonstrated that stromal rather than neutrophil-intrinsic galectin-3 was necessary for normal neutrophil entry into the airspaces. Live cell imaging studies revealed that extracellular galectin-3 directly increases neutrophil motility. Taken together, these data demonstrate that extracellular galectin-3 facilitates recruitment of neutrophils to the site of A. fumigatus infection, and reveals a novel role for galectin-3 in host defense against fungal infections.

Indexed as

AnimalsAspergillosisAspergillus fumigatusCell MovementFemaleGalectin 3HumansLungMaleMiceMice, Inbred C57BLNeutrophilsGalectin 3

Identifiers

PMID32750085
PMCPMC7428289
OpenAlexW3047076709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.